Published in Lancet on September 29, 1979
Cimetidine interaction with phenytoin. Br Med J (Clin Res Ed) (1981) 1.70
Cimetidine enhancement of cyclophosphamide antitumour activity. Br J Cancer (1982) 0.80
Histamine receptor antagonism and anti-tumour activity. Br J Cancer (1982) 0.79
Psychopharmacology in medical practice--the benefits and the risks. West J Med (1981) 0.75
Interaction of cimetidine and theophylline in two infants. Can Med Assoc J (1982) 0.75
The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest (1975) 4.65
Delayed clearance of diazepam due to cimetidine. N Engl J Med (1980) 3.45
Midazolam kinetics. Clin Pharmacol Ther (1981) 2.88
Telomere length in different tissues of elderly patients. Mech Ageing Dev (2000) 2.45
Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med (1980) 2.39
Affinity chromatographic isolation of the periplasmic maltose binding protein of Escherichia coli. FEBS Lett (1978) 1.71
Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol (1983) 1.69
Panfungal PCR and multiplex liquid hybridization for detection of fungi in tissue specimens. J Clin Microbiol (2000) 1.57
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.57
Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther (1982) 1.53
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet (1985) 1.41
Tripotassium dicitrato bismuthate: absorption and urinary excretion of bismuth in patients with normal and impaired renal function. Aliment Pharmacol Ther (1991) 1.39
Comparison of the pharmacokinetics of diazepam after single and subchronic doses. Eur J Clin Pharmacol (1976) 1.36
Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complex. Br J Clin Pharmacol (1990) 1.35
Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages. Mol Cell Biol (1995) 1.29
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther (1976) 1.28
Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter (1998) 1.27
An outbreak of Listeria monocytogenes serotype 3a infections from butter in Finland. J Infect Dis (2000) 1.27
Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol (1980) 1.26
Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet (1994) 1.25
Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: macrophages as a prominent source of interleukin-4. Am J Respir Cell Mol Biol (1997) 1.22
The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther (1974) 1.22
Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet (1992) 1.17
Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol (1981) 1.16
Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.14
Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans. J Clin Pharmacol (1985) 1.14
Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer (1996) 1.13
Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. Eur J Clin Pharmacol (1984) 1.12
Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis. Histochem Cell Biol (1998) 1.12
Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther (1977) 1.08
Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clin Pharmacol Ther (1977) 1.07
Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr (1981) 1.07
A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneimittelforschung (1985) 1.06
Analytical information is mandatory for pharmacokinetic papers. Clin Pharmacol Ther (1996) 1.05
Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology (1989) 1.00
Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol (2001) 1.00
Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. Br J Clin Pharmacol (1985) 0.99
Altered elimination of desmethyldiazepam in the elderly. Br J Clin Pharmacol (1979) 0.99
Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol (1989) 0.98
Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg (1997) 0.98
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter (2002) 0.97
Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther (1982) 0.97
Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol (1985) 0.97
Oroileal transit of slow release 5-aminosalicylic acid. Gut (1993) 0.96
Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet (2001) 0.96
Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin Pharmacokinet (1976) 0.95
Telomeres in neonates: new insights in fetal hematopoiesis. Pediatr Res (2001) 0.94
Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet (1996) 0.93
No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokinet (1988) 0.93
Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis? Ther Drug Monit (1980) 0.93
Transforming growth factor-beta1-induced activation of the Raf-MEK-MAPK signaling pathway in rat lung fibroblasts via a PKC-dependent mechanism. Biochem Biophys Res Commun (1998) 0.92
Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? Br J Clin Pharmacol (1986) 0.92
Intravenous benzodiazepines as anaesthetic agents: pharmacokinetics and clinical consequences. Acta Anaesthesiol Scand (1982) 0.92
Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies. Ther Drug Monit (1993) 0.91
Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol (1998) 0.90
Elevation of steady-state diazepam levels by cimetidine. Clin Pharmacol Ther (1981) 0.90
Clinical efficacy of oral 5-aminosalicylic acid in the treatment of inflammatory bowel disease. Am J Gastroenterol (1985) 0.90
High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man. J Chromatogr (1979) 0.90
High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine. J Chromatogr (1983) 0.90
Is N-acetylation of 5-aminosalicylic acid reversible in man? Br J Clin Pharmacol (1984) 0.89
Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet (1993) 0.89
Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scand J Gastroenterol (1987) 0.89
Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther (1998) 0.89
Does pH 6 beta-galactosidase activity indicate cell senescence? Mech Ageing Dev (1999) 0.89
Chronopharmacokinetic study with prolonged infusion of midazolam. Clin Pharmacokinet (1985) 0.89
Disposition and first-pass metabolism of ethanol in humans: is it gastric or hepatic and does it depend on gender? Clin Pharmacol Ther (1996) 0.88
Specific measurement of 5-aminosalicylic acid and its acetylated metabolite in human bile. Br J Clin Pharmacol (1983) 0.88
Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol (1994) 0.88
Frequent non-response to histamine H2-receptor antagonists in cirrhotics. Gut (1989) 0.88
Cyclic nucleotide phosphodiesterases of human and rat gastric mucosa. Naunyn Schmiedebergs Arch Pharmacol (1977) 0.88
Infectious liver foci in leukemia: comparison of short-inversion-time inversion-recovery, T1-weighted spin-echo, and dynamic gadolinium-enhanced MR imaging. Radiology (1994) 0.87
Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther (1990) 0.86
Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology (1995) 0.86
Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet (1994) 0.86
P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.85
Haemodilution therapy in ischaemic stroke: plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5. Eur J Clin Pharmacol (1987) 0.85
Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. Clin Pharmacokinet (1993) 0.85
Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol (1996) 0.85
Effect of omeprazole on nocturnal intragastric pH in cirrhotics with inadequate antisecretory response to ranitidine. Digestion (1991) 0.85
Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency. Clin Pharmacokinet (1993) 0.85
Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharmacokinet (1987) 0.85
Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol (1984) 0.84
Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2005) 0.83
Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology (1983) 0.83
Food intake and plasma binding of diazepam. Br J Clin Pharmacol (1977) 0.83
Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. Clin Pharmacol Ther (1994) 0.83
Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol (1983) 0.83
Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol (1978) 0.83
Protein binding and ivermectin estimations in patients with onchocerciasis. Clin Pharmacol Ther (1993) 0.82
Effect of five structurally diverse H2-receptor antagonists on drug metabolism. Biochem Pharmacol (1986) 0.82
Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther (2000) 0.82
Diagnosis of disseminated candidiasis by measurement of urine D-arabinitol/L-arabinitol ratio. J Clin Microbiol (1996) 0.82
Inhibitory effect of omeprazole on the metabolism of midazolam in vitro. Arzneimittelforschung (1990) 0.82
Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils. Dig Dis Sci (1994) 0.82
Once-daily dosing of gentamicin: experience with therapeutic drug monitoring and Bayesian pharmacokinetics. Ther Drug Monit (1994) 0.82
The effect of metoclopramide on the absorption of tolfenamic acid. Int J Clin Pharmacol Ther Toxicol (1982) 0.81
Pharmacokinetics of famotidine in man. Int J Clin Pharmacol Ther Toxicol (1987) 0.81
Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging (1997) 0.81
When are bioavailability studies required? A German proposal. J Clin Pharmacol (1998) 0.81
Determination of sulfapyridine and its major metabolites in plasma by high pressure liquid chromatography. J Chromatogr (1978) 0.80